Please login to the form below

ivabradine

This page shows the latest ivabradine news and features for those working in and with pharma, biotech and healthcare.

than Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine), which were both approved for heart failure in 2015.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.
Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart
Shire and Baxalta drugs among CHMP's latest recommendations

ANPHARM Przedsiębiorstwo Farmaceutyczne's Ivabradine Anpharm (ivabradine) for the treatment of stable chronic angina pectoris and chronic heart failure.
Amgen starts shipping Corlaner in US

Corlaner (ivabradine) - the first new medicine for chronic heart failure in the US in almost a decade - will be available in pharmacies before the end of the week, according to
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... on ivabradine sales on the back of US approval

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Heart failure therapy embarks on a new era

While Entresto has captured the headlines of late, there was another key development in HF therapy this year after Amgen secured approval in the US for Corlaner (ivabradine), a drug that ... Ivabradine is thought to be the first drug to work by
Deal Watch table for July 2013

100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... Over 40 European countries, Australia, New Zealand . ‡ North America. ‡‡ Amgen
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Add my company

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...